GPFA
INKT icon

Game Plan Financial Advisors’s MiNK Therapeutics INKT Stock Holding History

Game Plan Financial Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187 Hold
16
– – ﹤0.01% 415
2026
Q1 		$168 Hold
16
– – ﹤0.01% 316
2025
Q4 		$178 Hold
16
– – ﹤0.01% 318
2025
Q3 		$224 Hold
16
– – ﹤0.01% 320
2025
Q2 		$118 Hold
16
– – ﹤0.01% 336
2025
Q1 		$138 Sell
16
-1
-6% -$9 ﹤0.01% 341
2024
Q4 		$116 Hold
17
– – ﹤0.01% 357
2024
Q3 		$128 Hold
17
– – ﹤0.01% 367
2024
Q2 		$161 Hold
17
– – ﹤0.01% 360
2024
Q1 		$154 Hold
17
– – ﹤0.01% 413
2023
Q4 		$182 Buy
+17
New +$177 ﹤0.01% 416

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Game Plan Financial Advisors's INKT Position: Q2 2026 in Review

Game Plan Financial Advisors held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 16 shares worth $187. The position accounts for ﹤0.01% of the portfolio, ranked #415.

Game Plan Financial Advisors first reported a position in INKT in Q4 2023 and has held it in 11 quarters since. The position peaked at $224 in Q3 2025. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Game Plan Financial Advisors held 16 shares of MiNK Therapeutics worth $187 as of Q2 2026.
  • Game Plan Financial Advisors left its MiNK Therapeutics share count unchanged in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Game Plan Financial Advisors's portfolio in Q2 2026, its #415 holding.
  • Game Plan Financial Advisors first reported a position in MiNK Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Game Plan Financial Advisors's MiNK Therapeutics position peaked at $224 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Game Plan Financial Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.